Cargando…

Health Economic Aspects of Chimeric Antigen Receptor T-cell Therapies for Hematological Cancers: Present and Future

Since 2018, 2 chimeric antigen receptor (CAR) T-cell therapies received approval from the European Medicine Agency, with list prices around 320 000 Euro (€) (EUR) per treatment. These high prices raise concerns for patient access and the sustainability of healthcare systems. We aimed to estimate the...

Descripción completa

Detalles Bibliográficos
Autores principales: Heine, Renaud, Thielen, Frederick W., Koopmanschap, Marc, Kersten, Marie José, Einsele, Hermann, Jaeger, Ulrich, Sonneveld, Pieter, Sierra, Jorge, Smand, Carin, Uyl-de Groot, Carin A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8051992/
https://www.ncbi.nlm.nih.gov/pubmed/33880433
http://dx.doi.org/10.1097/HS9.0000000000000524
_version_ 1783679843900063744
author Heine, Renaud
Thielen, Frederick W.
Koopmanschap, Marc
Kersten, Marie José
Einsele, Hermann
Jaeger, Ulrich
Sonneveld, Pieter
Sierra, Jorge
Smand, Carin
Uyl-de Groot, Carin A.
author_facet Heine, Renaud
Thielen, Frederick W.
Koopmanschap, Marc
Kersten, Marie José
Einsele, Hermann
Jaeger, Ulrich
Sonneveld, Pieter
Sierra, Jorge
Smand, Carin
Uyl-de Groot, Carin A.
author_sort Heine, Renaud
collection PubMed
description Since 2018, 2 chimeric antigen receptor (CAR) T-cell therapies received approval from the European Medicine Agency, with list prices around 320 000 Euro (€) (EUR) per treatment. These high prices raise concerns for patient access and the sustainability of healthcare systems. We aimed to estimate the costs and budget impact associated with CAR T-cell therapies for current and future indications in hematological cancers from 2019 to 2029. We focused on the former France, Germany, Spain, Italy and the United Kingdom (EU-5) and the Netherlands. We conducted a review of list prices, health technology assessment reports, budget impact analysis dossiers, and published cost-effectiveness analyses. We forecasted the 10-year health expenditures on CAR T-cells for several hematological cancers in selected European Union countries. Nine cost-effectiveness studies were identified and list prices for CAR T-cell therapies ranged between 307 200 EUR and 350 000 EUR. Estimated additional costs for pre- and post-treatment were 50 359 EUR per patient, whereas the incremental costs of CAR T-cell therapy (when compared with care as usual) ranged between 276 086 EUR and 328 727 EUR. We estimated market entry of CAR T-cell therapies for chronic mantle cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia in 2021, 2022, 2022, 2022, and 2025, respectively. Cumulative expenditure estimates for existing and future indications from 2019 to 2029 were on average 28.5 billion EUR, 32.8 billion EUR, and 28.9 billion EUR when considering CAR T-cell therapy costs only, CAR T-cell therapy costs including pre- and post-treatment, and incremental CAR T-cell therapy costs, respectively. CAR T-cell therapies seem to be promising treatment options for hematological cancers but the financial burden on healthcare systems in the former EU-5 and the Netherlands will contribute to a substantial rise in healthcare expenditure in the field of hematology.
format Online
Article
Text
id pubmed-8051992
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-80519922021-04-19 Health Economic Aspects of Chimeric Antigen Receptor T-cell Therapies for Hematological Cancers: Present and Future Heine, Renaud Thielen, Frederick W. Koopmanschap, Marc Kersten, Marie José Einsele, Hermann Jaeger, Ulrich Sonneveld, Pieter Sierra, Jorge Smand, Carin Uyl-de Groot, Carin A. Hemasphere Article Since 2018, 2 chimeric antigen receptor (CAR) T-cell therapies received approval from the European Medicine Agency, with list prices around 320 000 Euro (€) (EUR) per treatment. These high prices raise concerns for patient access and the sustainability of healthcare systems. We aimed to estimate the costs and budget impact associated with CAR T-cell therapies for current and future indications in hematological cancers from 2019 to 2029. We focused on the former France, Germany, Spain, Italy and the United Kingdom (EU-5) and the Netherlands. We conducted a review of list prices, health technology assessment reports, budget impact analysis dossiers, and published cost-effectiveness analyses. We forecasted the 10-year health expenditures on CAR T-cells for several hematological cancers in selected European Union countries. Nine cost-effectiveness studies were identified and list prices for CAR T-cell therapies ranged between 307 200 EUR and 350 000 EUR. Estimated additional costs for pre- and post-treatment were 50 359 EUR per patient, whereas the incremental costs of CAR T-cell therapy (when compared with care as usual) ranged between 276 086 EUR and 328 727 EUR. We estimated market entry of CAR T-cell therapies for chronic mantle cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia in 2021, 2022, 2022, 2022, and 2025, respectively. Cumulative expenditure estimates for existing and future indications from 2019 to 2029 were on average 28.5 billion EUR, 32.8 billion EUR, and 28.9 billion EUR when considering CAR T-cell therapy costs only, CAR T-cell therapy costs including pre- and post-treatment, and incremental CAR T-cell therapy costs, respectively. CAR T-cell therapies seem to be promising treatment options for hematological cancers but the financial burden on healthcare systems in the former EU-5 and the Netherlands will contribute to a substantial rise in healthcare expenditure in the field of hematology. Lippincott Williams & Wilkins 2021-01-28 /pmc/articles/PMC8051992/ /pubmed/33880433 http://dx.doi.org/10.1097/HS9.0000000000000524 Text en Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Article
Heine, Renaud
Thielen, Frederick W.
Koopmanschap, Marc
Kersten, Marie José
Einsele, Hermann
Jaeger, Ulrich
Sonneveld, Pieter
Sierra, Jorge
Smand, Carin
Uyl-de Groot, Carin A.
Health Economic Aspects of Chimeric Antigen Receptor T-cell Therapies for Hematological Cancers: Present and Future
title Health Economic Aspects of Chimeric Antigen Receptor T-cell Therapies for Hematological Cancers: Present and Future
title_full Health Economic Aspects of Chimeric Antigen Receptor T-cell Therapies for Hematological Cancers: Present and Future
title_fullStr Health Economic Aspects of Chimeric Antigen Receptor T-cell Therapies for Hematological Cancers: Present and Future
title_full_unstemmed Health Economic Aspects of Chimeric Antigen Receptor T-cell Therapies for Hematological Cancers: Present and Future
title_short Health Economic Aspects of Chimeric Antigen Receptor T-cell Therapies for Hematological Cancers: Present and Future
title_sort health economic aspects of chimeric antigen receptor t-cell therapies for hematological cancers: present and future
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8051992/
https://www.ncbi.nlm.nih.gov/pubmed/33880433
http://dx.doi.org/10.1097/HS9.0000000000000524
work_keys_str_mv AT heinerenaud healtheconomicaspectsofchimericantigenreceptortcelltherapiesforhematologicalcancerspresentandfuture
AT thielenfrederickw healtheconomicaspectsofchimericantigenreceptortcelltherapiesforhematologicalcancerspresentandfuture
AT koopmanschapmarc healtheconomicaspectsofchimericantigenreceptortcelltherapiesforhematologicalcancerspresentandfuture
AT kerstenmariejose healtheconomicaspectsofchimericantigenreceptortcelltherapiesforhematologicalcancerspresentandfuture
AT einselehermann healtheconomicaspectsofchimericantigenreceptortcelltherapiesforhematologicalcancerspresentandfuture
AT jaegerulrich healtheconomicaspectsofchimericantigenreceptortcelltherapiesforhematologicalcancerspresentandfuture
AT sonneveldpieter healtheconomicaspectsofchimericantigenreceptortcelltherapiesforhematologicalcancerspresentandfuture
AT sierrajorge healtheconomicaspectsofchimericantigenreceptortcelltherapiesforhematologicalcancerspresentandfuture
AT smandcarin healtheconomicaspectsofchimericantigenreceptortcelltherapiesforhematologicalcancerspresentandfuture
AT uyldegrootcarina healtheconomicaspectsofchimericantigenreceptortcelltherapiesforhematologicalcancerspresentandfuture